Agoracom Blog Home

Posts Tagged ‘$TSXV’

Supreme Completes First Tranche of Previously Announced Private Placement

Posted by AGORACOM-JC at 8:54 AM on Monday, September 22nd, 2014

VANCOUVER, BRITISH COLUMBIA–(Sept. 22, 2014) -

NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

Supreme Pharmaceuticals Inc. (“Supreme” or the “Company“) (CSE:SL) is pleased to announce that it has closed the first tranche of its previously announced unit financing (see news releases dated August 15th and September 4, 2014) for total gross proceeds of $2,239,232.50 (the “Financing“). At closing, Supreme issued 8,956,930 Units (comprised of 8,956,930 common shares of the Company (“Common Shares“) and 4,478,465 Common Share purchase warrants (“Warrants“)) at a price of $0.25 per Unit. Each Warrant is exercisable for one Common Share at a price of $0.50 per share prior to September 22, 2015, subject to an accelerated expiry period upon 30-days notice by the Corporation to the subscriber, if the Common Shares trade at or above $0.70 for any five (5) day period during the term of the Warrants. Directors, senior officers and other insiders of the Corporation purchased an aggregate of 660,000 Units pursuant to the Financing. The Company paid finder’s fees of $65,320 and issued 287,280 Warrants to certain arm’s-length parties in the connection with the subscriptions of certain subscribers who participated in the private placement.

The Common Shares and Warrants issued pursuant to the private placement are subject to a hold period that expires January 23, 2015. Following closing, Supreme has 68,341,565 Common Shares issued and outstanding.

The Company intends to use the proceeds of the Financing for the development of the Company’s Kincardine facility and general working capital purposes. Based on the number of investors who have already submitted subscription agreements for the final tranche of the Financing, Supreme anticipates moving quickly towards a second closing prior to the end of September.

FORWARD-LOOKING INFORMATION

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the use of proceeds of the private placement, as well as the Company’s corporate strategy, participation in second tranche by those investors who have submitted subscription agreements to the Company but were not included in the first tranche, and having sufficient subscribers to close a second tranche. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation, including, without limitation, the Company’s ability to complete the remainder of the private placement. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
info@supreme.ca
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

INTERVIEW: Uragold Bay Resources Goes “Beyond The Press Release” to Discuss Recent Acquisition

Posted by AGORACOM-JC at 8:14 PM on Thursday, September 18th, 2014

UBR: TSX-V

Bernard Tourillon, Chairman, CEO and Director of Uragold Bay Resources goes “Beyond The Press Release” to discuss Letter Of Intent Regarding the Acquisition of 32 Claims Covering the Section of the 6.5 KM Long Historical Beauce Paleoplacer Gold Channel not Owned by Uragold.

Hub On AGORACOM / Corporate Profile / Watch Interview!

Newnote Financial Corp. to Start Trading on the OTCQB

Posted by AGORACOM-JC at 12:47 PM on Thursday, September 18th, 2014

Newnote Financial Corp. (the “Company”), (OTCQB: NWWTF CSE: NEU; FSE: 1W4) is pleased to announce that it has commenced trading on OTCQB®, the venture market for entrepreneurial and development stage companies. OTC Markets Group announced today that Newnote Financial has been verified for trading on OTCQB, effective September 18, 2014.

The OTCQB venture marketplace offers investors transparent trading in entrepreneurial and development stage U.S. and international companies. Beginning March 26, 2014, OTCQB companies will be required to meet new standards and eligibility requirements. To be eligible for OTCQB, companies must meet a minimum one-penny ($0.01) bid price test, be current in their reporting and undergo a new annual verification and management certification process designed to improve the information available to investors.

“We are very pleased to add Newnote Financial to our expanding universe of OTCQB companies,” commented Douglas Rogers, Managing Director of Merriman’s Capital Markets Advisory Group. “Advising our clients on best practices regarding their material information and financial reporting requirements is a key component of our advisory platform at Merriman. We look forward to supporting the Newnote Financial management team on the OTCQB market.”

Paul Dickson, President and CEO states: “This is an important milestone for the Company as it seeks to expand its presence in the United States of America. The Company is fully reporting in Canada and listed on the CSE Stock Exchange as well as the Frankfurt Stock Exchange. We are pleased to work with Merriman Capital Inc., whose hard work and diligence has allowed us to achieve our listing on the OTCQB.”

About Newnote

Newnote Financial Corp. is pioneering innovative crypto-currency and Bitcoin related software products and services geared at the growing business segment of this bourgeoning market. Newnote has positioned itself to be a leading contender in delivering opportunities to startup businesses world-wide and continues to create new opportunities for its clients and its shareholders. Newnote has a clear vision on the direction in which this new and unique business is headed and is continually adjusting and adopting new business practices in both technology and the policies & procedures required by banks and securities regulators.

About Merriman Capital, Inc.

Merriman Capital, Inc. is a full service investment bank and Broker-Dealer that facilitates efficient capital formation through a proprietary digital network, and offers Capital Markets Advisory and comprehensive Corporate Brokerage services for public and private companies. The firm also provides equity and options execution services for sophisticated investors and differentiated research for high growth companies. Merriman Capital, Inc. is a wholly owned brokerage subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is a leading advisory firm for publicly traded, high-growth companies.

Digital Capital Network, powered by Merriman Capital, is a capital marketplace that enables highly targeted and more efficient execution of transactions. Please visit our website for more information on how you can be a part of our Digital Capital Network: http://www.digitalcapitalnetwork.com. Digital Capital Network, Inc. is a wholly owned subsidiary of Merriman Holdings, Inc. All operations on the Digital Capital Network are currently being executed by Merriman Capital, Inc.

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) http://www.sipc.org/.

Company Contact Information

Paul Dickson
President, CEO & Director
Newnote Financial Corp.
CSE: NEU; FSE: 1W4
Suite 709-700 West Pender Street
Vancouver, BC V6C 1G8
direct: 604-800-6749
fax: 604-685-3833
web: www.newnote.com

Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of Newnote Financial Corp. The forward-looking information is based on certain key expectations and assumptions made by the company’s management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.

National Medical Marihuana Awareness and Outreach Strategy

Posted by AGORACOM-JC at 8:09 AM on Thursday, September 18th, 2014

 

VANCOUVER, BC / September 18, 2014 / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce along with it’s Joint Venture partner Lexaria Corp that Maureen McGrath Host of the popular CKNW Sunday Night Sex Show and a registered nurse will be leading a National Medical Marihuana Awareness and Outreach Strategy.

Maureen specializes in reproductive and sexual health for men and women. She is in private practice both in North Vancouver and at Cross Roads Clinic in Vancouver where she see patients with sexual health issues.

Maureen’s background includes business development, advocacy and clinical research in the field of spinal cord injury as well as the biotechnical industry. A regular health contributor to radio and television, she is also a guest columnist for the 24Hours Newspaper.

Maureen is a sought after lecturer and routinely educates physicians, nurses, allied health, industry and the public on reproductive and sexual health and other quality of life issues. She is an invited guest lecturer an at the University of British Columbia and Simon Fraser University where she shares her knowledge base with undergraduate and medical students on bladder, bowel & sexual health.

Maureen is the Chair of the BC Chapter of Canadian Nurse Continence Advisors. Maureen is on the Board of the College of Midwives of British Columbia and on the Advisory Board for the Be More Than A Bystander Program with EVA BC and the BC Lions. She is a long time Mentor with Minerva’s “Women Helping Women Work” Program. Maureen is passionate about raising awareness about violence against women in homes, on the street and in the workplace.

As part of the national outreach plan, Maureen will be educating physicians, pharmacists, health care practitioners, and the public on the benefits and responsible use of medical marijuana for patients in need. Enertopia intends for Maureen to reach out via town hall – style meetings as well as through the media, and to build a network of people interested in the medical marihuana field for advocacy of the safe and therapeutic use of medical marihuana.

Further details of the National educational awareness campaign will be forth coming over the coming weeks.

“I am excited at the opportunity to help educate the health community on the potential benefits of Medical Marihuana and its many uses,” stated Maureen McGrath

Enertopia is very happy to welcome Maureen to our advocacy group for education and learning for physicians and patients in search of natural healing options.” Stated President / CEO Robert McAllister.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Ken Faulkner, Business and Institutional Development: (250) 765-3630

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation of clean energy projects, oil & gas projects, , competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that Maureen McGrath will have any meaningful impact on doctor and patient awareness and or that the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: http://agoracom.com/portal/Small%20Cap%20Medical%20Ma

INTERVIEW: AGORACOM Sector Spotlight – $2.4B Medical Marijuana Industry

Posted by AGORACOM-JC at 12:25 PM on Wednesday, September 17th, 2014

Welcome to Sector Spotlight a production of AGORACOM in which we talk to CEOs and executives of companies in which we believe to be notable sectors so that you can potentially profit from them.

Today we’ll be discussing Medical Marijuana. Joining us is AGORACOM Chief Market Commentator Allan Barry Laboucan and Chris Bunka, CEO & President and Chairman of the board of Lexaria Corp.

Hub On AGORACOM / Corporate Profile / Watch Interview Now!

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Supreme Provides Construction Update

Posted by AGORACOM-JC at 8:47 AM on Wednesday, September 17th, 2014

VANCOUVER, BRITISH COLUMBIA–(Sept. 17, 2014) - Supreme Pharmaceuticals Inc. (the “Company”) (OTCBB:SPRWF)(CSE:SL) is pleased to report that it has made significant progress regarding the construction and required security implementation at its 342,000 square foot greenhouse facility located in Kincardine, Ontario (the “Greenhouse”).

Backed by strong support from the local municipality and business community, the Company has been able to move quickly to implement its proposed plan to produce up to 24,000,000 grams of medical marijuana, for which the Company has received a conditional pre-approval letter from Health Canada dated January 22, 2014 (the “Letter“). The Letter sets forth the conditions pursuant to which the Company’s application to be a Licensed Producer under the Marihuana for Medical Purposes Regulations (“MMPR“) may be granted, including the implementation and final inspection by Health Canada of certain cultivation, quality assurance, security and storage strategies. The Company is already in receipt of the required security clearances for its key personnel, as required by Health Canada. Locally, the Company has received all necessary approvals from the municipality, local law enforcement and local fire authorities. Marcomm Security Systems Group Inc., 2013 Security Integrator of the Year, is currently working to complete the installation and commissioning of the electronic security systems to be utilized at the Greenhouse. A level 8 storage vault capable of housing the Company’s production has been installed and the remaining physical security measures are near completion.

Peter Herburger, President and CEO of the Kincardine subsidiary stated, “We are thankful for the strong support from the local community, from the municipality, to the tradespeople to the local residents. With the support of Kincardine we have been able to maintain a construction schedule which will allow us to be ready to grow medical marijuana before the end of this year.”

The Company anticipates being ready for the pre-licenses inspection by Health Canada to verify the Company’s compliance with the requirements of the MMPR in November 2014 and looks forward to continuing its positive relationship with the regulator.

David Stadnyk, President and CEO of the Company stated, “Due to its size, local support the operational plan developed by management, the Greenhouse presents the opportunity to produce a large volume of high-quality, low-cost medical marijuana by applying commercial agriculture technology combined with the natural advantages of a greenhouse.”

FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the expected volumes from production; timing for completion of the Greenhouse; timing for implementation of required security measures; the timing for review of the Greenhouse by Health Canada, the subsequent issuance of a MMPR License and the conditions attached thereto; the construction schedule for the Greenhouse, and the expected start of commercial production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to acquire final MMPR license; delays in construction; additional competition in the marketplace; changes to the regulatory landscape; future jurisprudence regarding the MMPR process and implementation; the inability to source the technology and expertise needed to meet the conditions of the MMPR; the Company’s failure to attract and retain qualified horticultural personnel, unexpected conditions or diseases affecting production and general market conditions. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
info@supreme.ca
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Uragold and Fancamp Sign a Letter Of Intent Regarding the Acquisition of 32 Claims Covering the Section of the 6.5 KM Long Historical Beauce Paleoplacer Gold Channel not Owned by Uragold

Posted by AGORACOM-JC at 8:35 AM on Wednesday, September 17th, 2014

Montreal, Quebec / September 17 2014 / Uragold Bay Resources Inc. (“Uragold”) (TSX Venture: UBR) is pleased to announce that it has signed a letter of intent with Fancamp Exploration Ltd. (“Fancamp”) (TSX Venture: FNC) regarding the acquisition of 32 claims encircling Uragold’s Beauce Placer Gold Project located in the municipality of Saint-Simon-les-Mines in the Beauce region of southern Quebec.

Uragold’s current Beauce paleoplacer project, 5 claims situated between the Rang Chaussegros and the Rang Gustave, covers only twenty-six percent (26%) of the entire historical paleoplacer gold channel. When the transaction closes, Uragold’s claims block will cover the full 6.5 km long historical Paleoplacer gold channel.

 


Click Image To View Full Size

Figure 1. Historical Paleoplacer identified by Beauce Place Company in 1959 (Orange). Uragold original Beauce Claims (Blue). Zones were Uragold delineated an Inferred Resources in Mars 2014 (Thick Orange). Fancamp Claims subject to Letter of intent (Red).

In 1959, the Beauce Placer Gold Mining Company defined a drilled historical resource of 168,952 Au oz (12,978,710 m3 @ 0.405 g/m3) (June, 1959 – GM08785) on a channel defined as ranging from Rang St-Charles through to Rang Delery, Rang Chaussegros, Rang St-Gustave all the way to Rang 6. (V. Stuart-Williams, Beauce Placer Property NI 43-101 Technical Report, February 2014). All information such as resources estimates and grades herewith presented is historical in nature and while relevant, the information was obtained before the implementation of National Instrument 43-101 and as such does not meet National Instrument 43-101 reporting standards. The historical estimate should not be relied upon until the Company can confirm them.

Studies by Uragold of the auriferous basal till and the underlying saprolite suggest a close proximity source of gold, and since the acquired claims cover an extensive area of the Gilbert river valley this increases the chances that the unknown Bellechasse / Timmins type deposit mentioned in our March 27, 2014 press release will be found on Uragold claims.

Salient points of the non-binding letter of intent are:

  1. 1.Uragold and Fancamp intend to enter into a definitive written Agreement for the acquisition by Uragold of a 32 claim block contained in the Appalachian Properties that surrounded the Uragold Beauce Property (herein, collectively the “Claims”) (“The Acquisition”) within thirty (30) days.
    1. a.As consideration for the transfer and the sale of the Claims and related assets to Uragold, Uragold will issue, at the closing an amount equal to 8,000,000 Uragold Units. Each Unit will be comprised of 1 common share and 1 common share purchase warrant (the Warrant”) of Uragold.
    2. b.Each full Warrant will entitle Fancamp to purchase one common share of the capital stock during a period of 60 months from the date of the issuance of the Units. Each Warrant shall entitle Fancamp to purchase one (1) additional common share of Uragold at a price of C$0.20 per share during the first 24 months from the date of issuance of the units, at a price of C$0.30 from the start of the 25th month until the end of the 48th month, and at a price of C$0.40 per share at the start of the 49th month until the end of the 60th month.
  2. 2.Contemporaneously with the signing of the definitive Agreement:
    1. a.Uragold will make a cash payment of C$25,000 to Fancamp within six (6) months of the Signature of the definitive Agreement.
    2. b.Uragold will finance C$400,000 worth of exploration work on the Claims over the next 4 years, under the following schedule, Year 1: C$50,000, Year 2: C$75,000, year 3: C$100,000 and year 4: C$175,000.
    3. c.Uragold will grant Fancamp a three and one half percent (3.5 %) Gross Metal Royalty on any gold production extracted from the 32 Claim block acquired by Uragold.
  3. 3.Fancamp and Uragold will sign a Covenant regarding the sale of Uragold shares held by Fancamp.
    1. a.Included in the Covenant will be a Standstill agreement whereby Fancamp agrees not to sell any of its Uragold shares (“Standstill”) during a twelve (12) month period (“Standstill Period”) starting on the day of the issuance of the Uragold Units to Fancamp.
    2. b.The Covenant will also include a Change of Control Clause whereby in the event that a Change of Control event occurs at Fancamp, then either the Standstill Period will be automatically increased by thirty six (36) months or a new thirty six (36) months Standstill Period will start.
    3. c.Included in the Covenant will be a Vote with Management Clause whereby Fancamp agrees to votes all of its shares proxy in favor of Uragold Management.
  4. 4.Once Gold Mining operations have begun on the Claims purchased, Uragold will make a one-off cash payment of C$500,000 to Fancamp.

Both Parties are actively working to finalize the definitive written Agreement by end of next week, once both Parties obtain final board approval. The transaction is also subject to the approval of the TSX Venture Exchange.

Mr. Vivian Stuart-Williams, SACNASPS, working under Special Authorization #290 of the Quebec Order of Geologist, is an Independent Qualified Person as defined by National Instrument 43-101 that supervised the preparation of the information in this news release.

Patrick Levasseur, President and COO of Uragold stated that: “This acquisition will change the whole dynamics of the Beauce Paleoplacer Gold project. It could significantly increase the size and scope of our project.” Mr. Levasseur went on to add: “We are extremely pleased to have a highly experienced exploration company such as Fancamp as a large shareholder of Uragold”.

About Uragold Bay Resources Inc.

Uragold Bay Resources is a TSX-V listed Gold and High Purity Quartz exploration junior focused on generating free cash flow from mining operations. Our business model is centered on developing mining projects suited for smaller-scale start-up, (Capex < C$10M), that will generate high yield returns (IRR > 50%). Uragold will reach these goals by developing Quebec’s first placer mine in 50 years, the Beauce Placer Project developing and, in partnership with Golden Hope Mines, the Bellechasse-Timmins Gold Deposit.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact

Bernard J. Tourillon, Chairman and CEO
Patrick Levasseur, President and COO

Tel: (514) 846-3271

Lexaria Submits Health Canada Marijuana License Application

Posted by AGORACOM-JC at 8:16 AM on Wednesday, September 17th, 2014

 

Health Canada Marijuana License Application Submitted

Kelowna, BC / ACCESSWIRE / September 17, 2014 / Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the “Company” or “Lexaria”) reports that the joint venture with Enertopia Corp has submitted the Health Canada MMPR Licensed Producer application in July 2014, and that the application is currently in the Health Canada preliminary screening process. The actual submission of our license application had not been previously disclosed.

The Joint Venture is in correspondence with Health Canada frequently with respect to specific aspects of the licensing process which are being handled by Ontario Operations Manager Mr. Donald Shaxon, responsible person in charge. The Joint Venture has requested a Ready to Build letter from Health Canada.

The Burlington Joint Venture with Enertopia Corp (ENRT or TOP) has applied to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49%, as earlier disclosed.

The Burlington JV has requested a Ready to build letter from Health Canada once the application has been accepted from Health Canada.

Listed below are the Health Canada steps for becoming a licensed producer to be reached by way of the application and review process. There are no specific process time constraints for each step.

Step 1: Preliminary Screening
Step 2: Enhanced Screening
Step 3: Security Clearance
Step 4: Review
Step 5: Ready to build letter (if required by applicant)
Step 6: Pre-licence inspection
Step 7: Licensing

Health Canada has also been clear about the quantity of licenses to be issued, in contrast to certain marketplace speculation. The Health Canada website asks the question, “Is there a limit to how many production licences Health Canada will issue under the Marihuana for Medical Purposes Regulations (MMPR)?” And Health Canada answers the question with, “No. Health Canada will not impose a limit on the number of production licenses.”

Lexaria provides the above information to provide guidance and clarity to counter what at times appear to be flawed information in the community, of course acknowledging that the policies of third parties can change at any time.

The Joint Venture has been active in the local community and has met with the local policing authority, which is interested in conducting security training and swat team training at the Joint Venture facility. We are very pleased to be working closely with law enforcement and look forward to learning more from preventative and proactive security measures.

Lexaria also notes that the Ottawa project has conducted due diligence on and rejected the initial proposed building location in the greater Ottawa area as not likely to comply with the strict requirements of the MMPR. Additional locations in the area are being examined. The company will remain prudent in its efforts to ensure the maximum return on all our stakeholder’s investments.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria and no assurance that the corporate policies described herein will produce any benefit for the Company or its shareholders. There is no assurance that Health Canada will grant any license or ready to build letter to the Company at any time, with respect to the Company’s MMPR application.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

 

SOURCE: Lexaria Corp.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Enertopia Provides Burlington Lexaria JV Update

Posted by AGORACOM-JC at 8:11 AM on Wednesday, September 17th, 2014

VANCOUVER, BC / September 17, 2014 / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) announces the Burlington, Ontario Application is in the Health Canada Preliminary Screening process.

The company is pleased to advise shareholders that its Joint Venture partner, Lexaria Corp (LXRP), and the Company have submitted their application for Licensed Producer in July 2014 and are in regular correspondence with Health Canada with respect to specific aspects of the licensing process, which are being handled by Ontario Operations Manager Mr. Donald Shaxon as responsible person in charge.

The Burlington Joint Venture with Lexaria Corp has applied to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49% as disclosed on April 9, 2014 in Enertopia’s press release #201424.

The Burlington JV has requested a Ready to build letter from Health Canada once the application has been accepted from Health Canada, see step 5 below.

For those not familiar with the Health Canada process for becoming a licensed producer, below are the levels to be reached through the application process. Note there are no specific process times for each step, however one could progress from preliminary screening to ready to build letter in as little as 90 to 120 days depending on the application submitted to Health Canada:

Step 1: Preliminary Screening
Step 2: Enhanced Screening
Step 3: Security Clearance
Step 4: Review
Step 5: Ready to build letter (if required by applicant)
Step 6: Pre-licence inspection
Step 7: Licensing

The Joint Venture (JV) has been active in the local community and has received very good community and media support. The JV also met with the local policing authority and upon licensing by Health Canada we have proposed that the local police could conduct security and swat team training at the facility. We are very pleased to be working closely with law enforcement and look forward to their insights in preventative and proactive security measures.

Enertopia at this time publically acknowledges its support for the Lexaria Corp policy on the responsible use of medical marijuana announced on August 28, 2014. Therefore, Enertopia is establishing a corporate policy wherein we will not knowingly sell medical cannabis containing more than 0.3% THC to any medical marijuana patient who is under the age of 21, unless it is in a form specifically approved by relevant government health agencies.

“Enertopia’s overriding responsibility is to cause no harm and keep Medical Marijuana as a safe and secure option for patients in search of natural healing options.” Stated President / CEO Robert McAllister.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Ken Faulkner, Business and Institutional Development: (250) 765-3630

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential licensing and financing of its medical marihuana projects, evaluation of clean energy projects, oil & gas projects, , competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Burlington Joint Venture will obtain a license under MMPR and or that the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Excellent Results at New Lexaria Oil Well

Posted by AGORACOM-JC at 8:19 AM on Tuesday, September 16th, 2014

 

Excellent Results at New Lexaria Oil Well

Kelowna, BC /September 16, 2014 / Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the “Company” or “Lexaria”) is very pleased to report excellent oil production rates at the new PPF-12-7 oil well at Belmont Lake, Mississippi. The well is now flowing and selling oil.

As of Friday September 12, the well was producing approx 120 bo/d on a 12/64th choke. For Sept 13 it produced 119 bo/d on an 11/64th choke; and on Sept 14 it produced 119 bo/d on a 10/64th choke. No formation water has been produced. Flowing pressures increased each day as choke sizes were reduced, indicating healthy reservoir pressures. This is one of the highest flow rates ever for a Belmont Lake well, and more than meets Lexaria’s expectations. The 12-7 well is located further east than any other existing well in Belmont Lake field, further expanding the producing boundaries of the field which are still undetermined.

The operator and owners intend to restrict this well to 90 bo/d for the intermediate term on an even more restricted choke, and to monitor the well over time to optimize production in the short and long terms. This allows for more prudent operation of the well and field over time, as many Frio-formation wells can produce oil for as long as 10 or 15 years.

Although earlier sidewall core analysis indicated 19-20 feet (true vertical depth) of oil bearing pay, only the upper 8 feet of the well was perforated in order to stay above the oil/water contact zone.

“Taken within the context of this conservative perforation technique and the restriction from the small choke size, I view the oil production rates from this well as even more positive,” said Chris Bunka, President.

Lexaria congratulates its operator and co-owners of the 12-7 well as the Belmont Lake oil field continues to provide positive results.

Additional information, including longer term performance, will be released when available. Griffin & Griffin Exploration, LLC is the operator of the well which was drilled in Section 41, Township 2 North – Range 4 West of Wilkinson Country, Mississippi.

Lexaria retains a 42% working interest in the producing 12-1 and 12-3 wells; a 50% working interest in the suspended 12-4 and 12-5 wells; and a 13.3% working interest in the 12-7 well. Lexaria is actively reviewing all possible ways of maximizing value from the Belmont Lake oil field assets.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration because of mechanical, weather, operating, financial or other problems; capital expenditures that are higher than anticipated; or exploration opportunities being fewer than currently anticipated. There can be no assurance that road or site conditions will be favorable for field work; no assurance that well treatments or workovers will have any effect on oil or gas production; no assurance that oil field interconnections will have any measurable impact on oil or gas production or on field operations, and no assurance that any expected new well(s) will be drilled or have any impact on the Company. There can be no assurance that expected oil and gas production will actually materialize; and thus no assurance that expected revenue will actually occur. There is no assurance the Company will have sufficient funds to drill additional wells, or to complete acquisitions or other business transactions. Such forward looking statements also include estimated cash flows, revenue and current and/or future rates of production of oil and natural gas, which can and will fluctuate for a variety of reasons; oil and gas reserve quantities produced by third parties; and intentions to participate in future exploration drilling. Adverse weather conditions including but not limited to surface flooding can delay operations, impact production, and cause reductions in revenue. The Company may not have sufficient expertise to thoroughly exploit its oil and gas properties. The Company may not have sufficient funding to thoroughly explore, drill or develop its properties. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the completion of the 12-7 well or the new production facility will continue to produce commercial quantities of oil.

 

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.